Zhongzhi Pharma FY26 H1 profit attributable to owners rises 3.8% to RMB 9.1 million; revenue falls 10.3% to RMB 790 million

PUBT · 3d ago
Zhongzhi Pharma FY26 H1 profit attributable to owners rises 3.8% to RMB 9.1 million; revenue falls 10.3% to RMB 790 million
  • Zhongzhi Pharmaceutical posted revenue of RMB 789.96 million, down 10.3% from a year earlier.
  • Profit attributable to owners rose 3.8% to RMB 9.12 million; basic earnings per share held at RMB 0.011.
  • Gross profit fell 13.3% to RMB 418.19 million; gross margin narrowed 1.9 percentage points to 52.9%.
  • Pharmaceutical manufacturing revenue slid 12.2% to RMB 530.73 million; chain pharmacy revenue dipped 6% to RMB 259.24 million.
  • No interim dividend was recommended; the group cited inventory reduction adjustments and weaker pharmacy footfall amid competitive pressures.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhongzhi Pharmaceutical Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300629), on August 26, 2026, and is solely responsible for the information contained therein.